Photos Show Where US and China Have Sent Hospital Ships
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Both China and the United States, rivals in the contest for naval dominance in the Pacific, have recently deployed naval hospital ships.
USNS Comfort has been conducting a medical mission in Latin America since May 30, according to the U.S. Navy. Meanwhile, CNS Silk Road Ark departed for islands and reefs in the contested South China Sea on Monday, according to the Chinese military.
Why It Matters
China's navy is larger than its U.S. counterpart by hull count. While most of their vessels are designed for combat, both naval forces operate hospital ships that function as floating mobile medical facilities—supporting military missions, disaster relief and humanitarian operations.
The Chinese and American hospital ship deployments come after China commissioned its third oceangoing hospital ship, CNS Auspicious Ark, in May—a major milestone that now sees all three of China's theater command fleets equipped with their own hospital ships.
The United States hospital ship USNS Comfort anchors off the coast of St. George's, Grenada, during Continuing Promise 2025 on June 11, 2025.
The United States hospital ship USNS Comfort anchors off the coast of St. George's, Grenada, during Continuing Promise 2025 on June 11, 2025.
Mass Communication Specialist 2nd Class Rylin Paul/U.S. Navy
What To Know
The Comfort departed Naval Station Norfolk, Virginia, for a mission known as Continuing Promise 2025, aimed at providing patient care and technical expertise in community clinics across Grenada, Panama, Colombia, Ecuador, Costa Rica and the Dominican Republic.
The hospital ship arrived in St. George's, the capital of the Caribbean island of Grenada, on June 9, according to the U.S. Navy. In addition to providing medical care, American service members will renovate buildings and repair infrastructure damaged by natural disasters.
The Comfort is one of two Mercy-class hospital ships operated by the U.S. Navy, alongside USNS Mercy. The 63,000-ton ship—delivered to the Navy in 1987—is equipped with 1,000 patient beds, 11 general-purpose operating rooms and one interventional radiology suite.
Meanwhile, the Silk Road Ark departed the coastal city of Sanya—on China's southern Hainan Island—for its second "medical outreach voyage" since entering service in 2024.
"The mission focuses on meeting the medical needs of service members on islands," the Chinese military said in a press release. China controls a number of maritime features in the South China Sea, where its sovereignty claims overlap with those of several other countries.
The 10,000-ton Silk Road Ark is smaller than the Comfort, with a capacity of 300 patient beds. The vessel—China's second 10,000-ton oceangoing hospital ship—is capable of hosting eight surgical operations simultaneously, according to China Daily.
The Chinese hospital ship CNS Silk Road Ark departs from Sanya on China's southern Hainan Island for a medical mission in the South China Sea on June 16, 2025.
The Chinese hospital ship CNS Silk Road Ark departs from Sanya on China's southern Hainan Island for a medical mission in the South China Sea on June 16, 2025.
Chinese military
What People Are Saying
The U.S. Naval Forces Southern Command said in a press release on June 9:
"[Continuing Promise 2025] marks the 16th mission to the region since 2007 and the eighth aboard [USNS] Comfort. The mission will foster goodwill, strengthen existing partnerships with partner nations, and encourage the establishment of new partnerships among countries, non-federal entities, and international organizations."
The Chinese military said in a press release on Tuesday: "[CNS Silk Road Ark's] major tasks include medical rescue and evacuation of the wounded at sea, international humanitarian medical service, emergency medical rescue in major disasters, and foreign military medical exchanges and cooperation."
What Happens Next
It remains to be seen whether China will expand its fleet of hospital ships as part of its naval modernization efforts, thereby increasing operational flexibility for deployments across different regions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
31 minutes ago
FDA approves the world's only twice-a-year shot to prevent HIV
WASHINGTON -- The U.S. has approved the world's only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot — a drug called lenacapvir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. 'This really has the possibility of ending HIV transmission,' said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research. Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills. But upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said "gaping holes in the system" in the U.S. and globally "are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' even as little as twice a year. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. It's given as two injections under the skin of the abdomen, leaving a small 'depot' of medication to slowly absorb into the body. Gilead didn't immediately announce its price. The drug only prevents HIV transmission – it doesn't block other sexually transmitted diseases. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' 'Everyone in every country who's at risk of HIV needs access to PrEP,' added Dr. Gordon Crofoot of Houston, who helped lead the study in men. 'We need to get easier access to PrEP that's highly effective like this is.'
2 hours ago
Social Security fund may run dry sooner than previously expected, trustees say
The trust funds for Social Security and Medicaid will run out of money in as little as 8 years, a shorter time frame than previously estimated, according to a report issued Wednesday by the programs' trustees. The Social Security fund will run dry in 2033, unless Congress combines the program's old-age and disability funds, in which case insolvency would arrive in 2034, the report found. A finding last year predicted Social Security would become insolvent in 2035 or 2036. Medicare's hospital insurance fund is expected to run out of money in 2033, the report said. 'Social Security and Medicare are vital programs that support tens of millions of Americans across the country,' U.S. Secretary of Treasury Scott Bessent said in a statement. 'This data underscores the need for lawmakers to take action to support the long-term viability of these programs.' If Congress fails to address the projected budget shortfalls, automatic cuts will dial back Social Security benefits by 23% and Medicare hospital benefits by 11% in 2033, the report found. Roughly 66 million Americans receive medical coverage through Medicare, while 70 million people are set to receive Social Security benefits this year. The Social Security and Medicare trust funds generate revenue through a payroll tax paid by employees and employers, setting the income apart from the overall federal budget. The programs routinely spend more money than they take in through such taxes. President Donald Trump has vowed to safeguard Social Security and Medicare, even as the White House pursues spending cuts at other federal programs and agencies. The Department of Government Agency, formerly led by Elon Musk, sought to eliminate what it described as 'waste, fraud and abuse' in Social Security and Medicare. In March, the White House backed such efforts in a memo. Last year, the Government Accountability Office, a federal agency, estimated that taxpayers lose as much as $521 billion annually to fraud, much of which occurs in entitlement programs like Medicare. The Centers for Medicare and Medicaid Services (CMS) have stopped more than $100 billion in potentially fraudulent expenditures over recent months, the agency said in a statement. Still, those possible savings make up a fraction of roughly $1.9 trillion in spending for Medicare and Medicaid in 2023, the most recent year for which data is available. 'Medicare provides essential coverage for millions of American seniors, but this year's report underscores the urgent need for serious, sustained reform to secure its long-term future,' CMS Administrator Mehmet Oz said in a statement.
Chicago Tribune
2 hours ago
- Chicago Tribune
FDA approves the world's only twice-a-year shot to prevent HIV
WASHINGTON — The U.S. has approved the world's only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot — a drug called lenacapvir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. 'This really has the possibility of ending HIV transmission,' said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research. Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills. But upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said 'gaping holes in the system' in the U.S. and globally 'are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' even as little as twice a year. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. It's given as two injections under the skin of the abdomen, leaving a small 'depot' of medication to slowly absorb into the body. Gilead didn't immediately announce its price. The drug only prevents HIV transmission – it doesn't block other sexually transmitted diseases. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' 'Everyone in every country who's at risk of HIV needs access to PrEP,' added Dr. Gordon Crofoot of Houston, who helped lead the study in men. 'We need to get easier access to PrEP that's highly effective like this is.'
